Dark Forest Capital Management’s Esperion Therapeutics ESPR Stock Holding History

Dark Forest Capital Management’s Portfolio ESPR Stock Details ESPR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-60	Closed	-$95	–	1146
2023 Q1	$95	Buy	+60	New	+$310	﹤0.01%	1126
2022 Q4	–	Sell	-550	Closed	-$4K	–	1246
2022 Q3	$4K	Buy	550 +468	+571%	+$3.21K	﹤0.01%	928
2022 Q2	$1K	Buy	+82	New	+$465	﹤0.01%	782
2021 Q4	–	Sell	-596	Closed	-$7K	–	1532
2021 Q3	$7K	Sell	596 -388	-39%	-$5.65K	﹤0.01%	1042
2021 Q2	$21K	Buy	+984	New	+$23.7K	0.01%	559

Other funds holding ESPR

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return

Dark Forest Capital Management's ESPR Position: Q2 2023 in Review

Dark Forest Capital Management sold out of Esperion Therapeutics (ESPR) in Q2 2023, closing a stake of 60 shares — an estimated $95 sold.

Dark Forest Capital Management first reported a position in ESPR in Q2 2021 and held it in 5 quarters. The position peaked at $21K in Q2 2021. 124 funds tracked by Wall St. Rank hold ESPR as of Q2 2023.

Dark Forest Capital Management reported no remaining Esperion Therapeutics position as of Q2 2023 after selling out during the quarter.
Dark Forest Capital Management sold 60 Esperion Therapeutics shares in Q2 2023, an estimated $95.
Dark Forest Capital Management first reported a position in Esperion Therapeutics in Q2 2021 and held it in 5 quarters.
Dark Forest Capital Management's Esperion Therapeutics position peaked at $21K in Q2 2021.
124 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2023.

Based on Dark Forest Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.